Physician profile
Mohammad Pazooki
NPI 1881851616
$3,386.37
in general payments reported to CMS, 2019-2025
44 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,112 · 2020: $850 · 2021: $163 · 2022: $199 · 2023: $12.70 · 2024: $49.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $40.45 · Education: $22.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $40.45 |
| Education | $22.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $425.79 | 2019-2020 | |
| Janssen Biotech, INC. | $247.56 | 2019-2022 | |
| Genentech USA, INC. | $221.89 | 2019-2024 | Phesgo |
| Sanofi-Aventis U.S. LLC | $208.43 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $180.68 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $163.27 | 2019-2021 | |
| Pfizer INC. | $162.83 | 2019-2020 | |
| Genzyme Corporation | $160.53 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $134.35 | 2019-2020 | |
| Epizyme, INC. | $99.95 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $98.71 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $95.50 | 2019-2020 | |
| Celgene Corporation | $84.81 | 2019 | |
| Astellas Pharma US INC | $79.80 | 2019-2020 | |
| Exelixis INC. | $73.03 | 2019-2020 |
Show all 43 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$30,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Pazooki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.